Acrivon Therapeutics Announces It Will Present Data From AP3 Generative Phosphoproteomic Analyses Of ACR-2316-Regulated CDK1-, CDK2-, And PLK1-Induced Pathways at a American Association For Cancer Research Annual Meeting April 25-30, 2025 In Chicago, Illinois

Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically

Phase 1 trial of ACR-2316 ahead of schedule with three dose-escalation cohorts completed; solid tumor shrinkage already observed at dose level three, well below the projected recommended Phase 2 dose

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, announced it will present data from AP3 Generative Phosphoproteomic analyses of ACR-2316-regulated CDK1-, CDK2-, and PLK1-induced pathways at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025 in Chicago.

ACR-2316 is a selective WEE1/PKMYT1 inhibitor, which has shown differentiated and superior anti-cancer activity in preclinical studies against clinical benchmark inhibitors and is currently in an ongoing Phase 1 monotherapy clinical study. Using AP3-based Indication Finding and AP3-based analyses of in-house and publicly available data, the company is enrolling patients in the clinical trial with certain high unmet need solid tumor types selected based on predicted sensitive to ACR-2316. Dose levels (DLs) 1, 2 and 3 have been cleared without safety concerns or dose-limiting toxicities (DLTs) by the safety review committee, and DL4 is now enrolling. Drug target engagement was observed already at DLs 1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses. Notably, initial clinical activity of ~25% RECIST tumor shrinkage and reduction of metastatic lesions throughout the chest, abdomen and pelvis was already observed at DL3.

"ACR-2316 was rationally designed through AP3-based SAR to induce desirable anti-tumor pathway effects inside a cell and to overcome the limitations of single-target WEE1 and PKMYT1 inhibitors. Our Phase 1 study of ACR-2316 is advancing rapidly, and we are excited about these encouraging observations, including early clinical activity," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. "Uniquely enabled by our Generative Phosphoproteomics AP3 platform, ACR-2316 is optimized to achieve superior single-agent activity, complete tumor regression and pro-apoptotic tumor cell death with a favorable therapeutic index, as demonstrated in preclinical studies. At AACR, we look forward to sharing exciting data which show how signaling pathways acted upon by ACR-2316 mechanistically deliver potent activity."